Incepta introduces Papilovax, vaccine for cervical cancer | The Daily Star
Skip to main content
T
Tuesday, March 21, 2023
The Daily Star
E-paper Today's News বাংলা
  • Home
  • News
  • Opinion
  • Health
  • Sports
  • Business
  • Entertainment
  • Culture
  • Life & Living
  • Youth
  • Tech & Startup
  • Feature
    • Lifestyle
    • Arts & Entertainment
    • Showbiz
    • Star Health
    • Satireday
    • Shout
    • Toggle
    • Star Literature
    • In Focus
    • Star Youth
    • Shift
    • Daily Star Books
    • Roundtables
    • Star Holiday
    • weekend read
  • More
    • Environment
    • NRB
    • Supplements
    • Law & Our Rights
  • E-paper
  • বাংলা
Search Epaper T
  • Today's News
  • Home
  • News
  • Opinion
  • Health
  • Sports
  • Business
  • Entertainment
  • Culture
  • Life & Living
  • Youth
  • Tech & Startup
  • Feature
    • Lifestyle
    • Arts & Entertainment
    • Showbiz
    • Star Health
    • Satireday
    • Shout
    • Toggle
    • Star Literature
    • In Focus
    • Star Youth
    • Shift
    • Daily Star Books
    • Roundtables
    • Star Holiday
    • weekend read
  • More
    • Environment
    • NRB
    • Supplements
    • Law & Our Rights

  • About Us
  • Contact Us
  • Apps
  • Comment Policy
  • RSS
  • Sitemap
  • Advertisement
  • Newsletter
  • Privacy Policy
  • Conference Hall
  • Archives
Business

Incepta introduces Papilovax, vaccine for cervical cancer

Star Business Report
Mon Jul 18, 2022 07:29 PM Last update on: Mon Jul 18, 2022 07:35 PM

Incepta Vaccine Ltd, the country's first vaccine manufacturing company, has launched cervical cancer vaccine Papilovax in Bangladesh.

The Papilovax vaccine protects against cervical cancer by preventing the HPV virus responsible for cervical cancer, Incepta said in a statement today.

For all latest news, follow The Daily Star's Google News channel.

Cervical cancer is the second leading cause of female cancer deaths in Bangladesh. The main cause of death in this cancer is ignorance and years of neglect, according to the statement.

Every year more than 10,000 women die of cervical cancer in the country and more than 5 crore women are at risk of it.

By giving this vaccine to all healthy women from 9 to 45 years, Bangladesh will go a long way in eradicating cervical cancer. This vaccine will help meet the long-standing demand in the country.

Papilovax is also marketed in modern pre-filled syringes. It should be noted here that the full dose in pre-filled syringes is manufactured in aseptic environment and marketed at controlled temperature in fully sterile packaging.

Direct administration of vaccine in pre-filled syringes is easy and does not require separate dosing. As a result, the vaccine can be administered more safely and easily at the correct dose.

Incepta Vaccines Ltd is the country's first life-saving international standard vaccine manufacturing company, according to the statement.

The company has already managed to gain immense recognition and appreciation within and outside the country.

The main objective of this organisation is to protect the vast population of Bangladesh as well as the developing world from various infectious diseases by providing affordable vaccines.

Related topic:
Incepta PharmaceuticalsIncepta Vaccine Ltdcervical cancer vaccine Papilovax
Apple Google
Click to comment

Comments

Comments Policy

Related News

Detecting cholera in 15 minutes

diagnostic test kit for cholera disease

icddr,b develops rapid diagnostic test kit for cholera

৫৯ মিনিট আগে|বিদ্যুৎ ও জ্বালানি

ঢাকার যেসব এলাকায় বুধবার গ্যাস থাকবে না

বুধবার সকাল ১০টা থেকে সন্ধ্যা ৬টা পর্যন্ত ৮ ঘণ্টা এসব এলাকার গ্যাস সরবরাহ বন্ধ থাকবে

১ ঘণ্টা আগে|অপরাধ ও বিচার

রাষ্ট্রপতি নির্বাচন প্রক্রিয়ার বৈধতা চ্যালেঞ্জ করে রিট আপিল বিভাগেও খারিজ

The Daily Star
Journalism without fear or favour
  • About Us
  • Contact Us
  • Apps
  • Comment Policy
  • RSS
  • Sitemap
  • Advertisement
  • Newsletter
  • Privacy Policy
  • Conference Hall
  • Archives
© 2023 thedailystar.net | Powered by: RSI LAB
Copyright: Any unauthorized use or reproduction of The Daily Star content for commercial purposes is strictly prohibited and constitutes copyright infringement liable to legal action.
X